Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-08 13:35Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3][6]. - The lawsuit claims that Jasper Therapeutics made false statements regarding its manufacturing controls and the suitability of its products for clinical trials, which misled investors about the company's financial and business prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own history of successful settlements and recognition in the field [4]. - The firm has achieved significant recoveries for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].